Cambridge Cognition Launches Aqua Automated Quality Assurance Solution

News
Article

Mixture to be used for central nervous system clinical trials.

Central Organ of Human Nervous System Brain Anatomy. Image Credit: Adobe Stock Images/magicmine

Image Credit: Adobe Stock Images/magicmine

Cambridge Cognition announced that it has officially launched Aqua, its automated quality assurance solution for central nervous system (CNS) clinical trials. Powered by the company’s winterlight speech and language platform, the solution is the first product of its kind to be available on the market.

“Aqua is an entirely new solution for the clinical trials market providing a level of quality assurance that was not possible before, from a cost or time perspective, with traditional reviews by medical experts,” said Matthew Stork, CEO, Cambridge Cognition. “We acquired Winterlight Labs intending to commercialize their innovative verbal clinical assessments and, by launching Aqua, we have achieved the first of our product goals. We are also really pleased to have already won a client for Aqua as we expect this will provide us with an excellent case study for future sales.”

Reference: Launch of automated quality assurance for clinical trials. Cambridge Cognition. October 24, 2023. Accessed October 25, 2023. https://cambridgecognition.com/launch-of-automated-quality-assurance-for-clinical-trials/

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.